STOCKHOLM, March 20, 2020 /PRNewswire/ -- IRRAS's annual
report 2019 has today been published on the company's website.
The report is available on:
https://investors.irras.com/en/reports-presentations
The financial year covers the period from 1 January to
31 December 2019.
About IRRAS
IRRAS is a global medical device company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier Growth
Market (ticker: IRRAS). Redeye AB is certified adviser of the
company with email, certifiedadviser@redeye.se, or phone +46 8
121 576 90.
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
President and CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on March 20, 2020 at 4:30
p.m. (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-publishes-annual-report-for-2019,c3065081
The following files are available for download:
https://mb.cision.com/Main/16550/3065081/1215127.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/irras-publishes-annual-report-for-2019-301027580.html
SOURCE IRRAS